Related by context. All words. (Click for frequent words.) 74 pancreatic gastric 72 recurrent refractory 72 Proxinium TM 69 LHRH receptor positive 68 metastatic colorectal 68 colorectal liver 67 metastatic bladder 67 metastatic pancreatic 67 Vicinium TM 67 neck SCCHN 66 recurrent metastatic 66 receiving chemoradiation therapy 65 CYT# potent vascular disrupting 65 EGFR expressing 65 pancreatic colon 65 metastatic HER2 positive 65 papillary renal cell carcinoma 65 multicenter Phase II 65 pancreatic colorectal 65 metastatic squamous cell carcinoma 65 BRIM2 64 Proxinium 64 nonmetastatic 64 pancreatic prostate 64 chemoradiotherapy 64 lung esophageal 64 LBH# 64 zalutumumab 64 colorectal ovarian 64 platinum refractory 64 acute peripheral arterial 64 humanised monoclonal antibody 64 tumors GIST 64 paclitaxel carboplatin 63 5 fluorouracil leucovorin 63 Sudhir Agrawal D.Phil 63 metastatic carcinoma 63 occlusion PAO 63 intravesical infusion therapy 63 droopy bows 63 recurrent NSCLC 63 basal cell carcinoma BCC 63 SCCHN 63 non resectable metastatic 63 carboplatin paclitaxel 63 lung malignant melanoma 63 metastatic malignant 63 metastatic androgen independent 63 cell carcinoma RCC 63 metastatic relapsed 63 Glioblastoma Multiforme 63 metastatic gastric 63 neck squamous cell 62 sodium thiosulfate STS 62 IV metastatic melanoma 62 TheraCIM h R3 62 nodal metastasis 62 biliary tract cancer 62 stage IIIb IV 62 gastric adenocarcinoma 62 epithelial ovarian 62 colorectal lung 62 Squamous Cell Carcinoma 62 gastrointestinal stromal 62 fallopian tube carcinoma 62 urothelial carcinoma 62 anti PlGF 62 docetaxel Taxotere R 62 phase IIb clinical 62 bladder prostate 62 fallopian tube cancers 62 refractory metastatic 62 nonsmall cell lung cancer 62 pancreas colon 62 including eniluracil ADH 62 unresectable tumors 62 sorafenib tablets 62 surgically resected 62 carcinoma HCC 62 systemic anaplastic large 62 node metastasis 62 docetaxel Taxotere ® 62 non resectable 62 bladder ovarian 62 Aplidin 62 OncoVex 61 fluoropyrimidine 61 recurrent glioblastoma multiforme 61 plus gemcitabine 61 plus 5-FU/LV 61 Surgical resection 61 lung carcinomas 61 Degarelix 61 MAGE A3 ASCI 61 ovarian colon 61 metastatic malignant melanoma 61 metastatic GIST 61 recurrent malignant glioma 61 keloid scarring 61 ThermoDox R 61 ovarian colorectal 61 chemoradiation therapy 61 systemic ALCL 61 kidney urologic 61 chimeric monoclonal antibody 61 nasopharyngeal carcinoma 61 virus HCV protease inhibitor 61 triggers apoptosis programmed 61 basal cell skin 61 ADVEXIN therapy 61 RCW breast cancer 61 injected subcutaneously 61 severe oral mucositis 61 BCG refractory carcinoma 61 gastrointestinal stromal tumors GIST 61 ovarian pancreatic 61 cervical lymph nodes 61 pancreatic ovarian 61 Aflibercept 61 tongue mouth pharynx 61 benign prostatic hyperplasia enlarged 61 Deforolimus 61 cell lymphoma CTCL 61 ZACTIMA 61 lymphomas leukemias 61 sorafenib Nexavar 61 biliary cancer 61 prostate carcinoma 61 lung pancreatic 61 pediatric malignancies 61 ovarian lung 61 metastatic adenocarcinoma 61 bile duct cancers 61 resectable pancreatic cancer 61 rheumatoid arthritis RA psoriatic 61 aflibercept VEGF Trap 61 receptor tyrosine kinase inhibitor 61 colorectal gastric 61 pulmonary metastasis 61 metastatic renal 61 ovarian bladder 61 R Saizen R 61 ZACTIMA TM ZD# 60 cetuximab Erbitux R 60 retinal vein occlusion induced 60 trial evaluating PRX# 60 thymoma 60 pancreatic adenocarcinoma 60 Cotara ® 60 mitoxantrone plus 60 acetonide FA 60 pain palliation 60 GVAX ® 60 Folfox 60 delivers fluocinolone acetonide FA 60 INSPIRE Trial Phase III 60 stage IIIB 60 chemotherapy cisplatin 60 colorectal adenocarcinoma 60 cervical anal 60 phase IIb study 60 radiation sensitizer 60 HuMax EGFr 60 budesonide foam 60 induce apoptosis programmed 60 tumor xenograft models 60 palliative radiotherapy 60 Soft Tissue Sarcoma 60 syngeneic 60 concurrent chemoradiation 60 BRAF inhibitor 60 cisplatin resistant 60 Annamycin 60 targeting miR 60 esophageal gastric 60 Randomized Phase II 60 BRAF mutant 60 IRX 2 60 demonstrated antitumor activity 60 liposomal doxorubicin 60 IV NSCLC 60 randomized Phase IIb 60 oral ridaforolimus 60 fosbretabulin 60 squamous cell carcinoma SCC 60 colorectal pancreatic 60 malignant ascites 60 Hormone Refractory Prostate Cancer 60 recurrent glioblastoma 60 Amrubicin 60 Enzastaurin 60 MGd 60 GRN# 60 huC# DM4 60 taxane resistant 60 unresectable locally advanced 60 gastroesophageal junction 60 pancreatic carcinoma 60 parathyroid carcinoma 60 pegylated liposomal doxorubicin 60 paclitaxel poliglumex 60 essential thrombocythemia ET 60 humanised antibody 60 transarterial 60 orally administered inhibitor 60 MKC# MT 60 unresectable stage 60 Capesaris 60 ELACYT 60 dasatinib Sprycel ® 60 Xeloda ® 60 Combination REOLYSIN R 59 refractory colorectal cancer 59 Cetuximab Erbitux 59 liver colon rectal 59 carcinoma HNSCC 59 superficial bladder cancer 59 diseases osteoarthritis osteoporosis 59 Mohs micrographic surgery 59 lymphoma CTCL 59 taxane chemotherapy 59 luteinizing hormone releasing 59 IgG1 monoclonal antibody 59 IV melanoma 59 leiomyosarcoma 59 trastuzumab Herceptin R 59 induced oral mucositis 59 adjuvant colon cancer 59 antibody MAb 59 Alessandro Riva 59 Imprime PGG 59 Malignant Melanoma 59 ductal carcinomas 59 ovarian prostate 59 FUSILEV enhances 59 evaluating T DM1 59 Cannabinor 59 intraepithelial neoplasia 59 Advexin 59 IMiDs ® compound 59 ADVEXIN 59 taxane chemotherapy administered 59 visceral metastases 59 lintuzumab SGN 59 asthenia pain 59 refractory cutaneous T 59 Safinamide 59 Amgen Neulasta R 59 brain metastases originating 59 vagina cervix 59 recurrent DVT 59 pancreatic lung 59 chronic myeloid 59 cervical prostate 59 prostate cancer mCRPC 59 LymphoStat B belimumab 59 relapsing remitting MS RRMS 59 cediranib 59 hypervascular tumors 59 epithelioid 59 HGS ETR1 mapatumumab 59 Phase IIb clinical trials 59 CIMZIA TM certolizumab pegol 59 deCODE ProstateCancer TM 59 axilla 59 novel VDA molecule 59 Diabetic Macular Edema DME 59 intravenous belinostat 59 cisplatin gemcitabine 59 Papillary 59 advanced metastatic renal 59 #mg BID [001] 59 chemosensitizer 59 Omacetaxine 59 Skin grafting 59 bone marrow reticulin deposition 59 Phase #b/#a clinical 59 gefitinib Iressa 59 prostate cancer HRPC 59 NMIBC 59 5 FU leucovorin 59 acute myeloid 59 CTEPH 59 Factor VIIa 59 cutaneous T 59 neuroendocrine carcinoma 59 Stage IIB 59 vinca alkaloid 59 prostate carcinomas 59 Sapacitabine 59 somatostatin analog 59 gastrointestinal stromal tumor 59 vapreotide acetate 59 superficial basal cell carcinoma 59 Hsp# Inhibitor 59 refractory ovarian cancer 59 nasopharyngeal cancer 59 keloid scars 59 mertansine 59 oral deforolimus 59 class mGluR5 inhibitor 59 FOLFOX6 59 anaplastic astrocytoma AA 59 Trabectedin 59 CEQ# 59 fibroma 58 metastatic colorectal carcinoma 58 vaginal candidiasis 58 peritoneal cancer 58 stage IIIB IV 58 pertuzumab 58 breast pancreatic 58 pancreas esophagus 58 grade squamous intraepithelial 58 targeted radiotherapeutic 58 PF # [002] 58 PANVAC VF 58 mapatumumab 58 OMP #M# 58 castrate resistant prostate cancer 58 hypoxia activated prodrug 58 EGFR tyrosine kinase inhibitor 58 hepatitis C viral infection 58 HBeAg negative 58 Evoltra ® 58 leukemia AML 58 OvaRex ® MAb 58 Bayer HealthCare Onyx Pharmaceuticals 58 Hepatocellular Carcinoma HCC 58 pleomorphic 58 CYT# vascular disrupting 58 toenail onychomycosis 58 esophageal tumors 58 IMC A# 58 lenalidomide Revlimid R 58 cancer mCRC 58 hypertrichosis occurred 58 HER2 positive metastatic breast 58 IMC #B 58 R sorafenib tablets 58 postoperative chemotherapy 58 relapsed MM 58 castrate resistant 58 comparator arm 58 gastrointestinal stromal tumors 58 Phase 2b Clinical Trial 58 Fludara ® 58 PNP inhibitor 58 Amgen Neulasta ® 58 myelodysplastic myeloproliferative diseases 58 BAY #-# 58 refractory gastrointestinal stromal 58 Sezary syndrome 58 bronchogenic 58 EOquin TM 58 locoregional recurrence 58 allogeneic epidermal 58 Romidepsin 58 Exherin TM 58 novel therapeutic antibodies 58 Fluorouracil 58 ALA PDT 58 dysplastic lesions caused 58 Prednisone Against Refractory 58 colorectal bladder 58 Zybrestat 58 completely resected 58 ovary uterus 58 metastatic liver 58 cervix anus 58 localized renal 58 advanced hepatocellular carcinoma 58 relapsed mantle 58 pheochromocytoma 58 anthracyclines taxanes 58 cutaneous lupus 58 squamous cell cancer 58 genitourinary tract 58 PSMA ADC 58 CLL SLL 58 Mitomycin C 58 stage IIIb 58 aneurysms AAA 58 brand ciclesonide HFA 58 AEG# 58 structure infections ABSSSI 58 Phase 1b clinical trials 58 huN# DM1 58 Squamous Cell 58 esophagus bladder 58 T1c 58 gemcitabine carboplatin 58 recurrent glioblastoma multiforme GBM 58 EGFR TKI 58 resistant ovarian cancer 58 vemurafenib 58 gastrointestinal cancers 58 gastrointestinal toxicities 58 deep venous thromboses 58 5-FU/LV 58 incised wound 58 GEM OS2 58 axitinib 58 colorectum 58 evaluating tivozanib 58 pan HDAC inhibitor 58 FOLOTYN ® 58 corticosteroid dexamethasone 58 non splenectomized 58 resectable 58 IMiDs R 58 monoclonal antibody conjugated 58 Iluvien ® 58 ZOLINZA 58 sunitinib Sutent 58 cervix uteri 58 orally inhaled 58 depsipeptide 58 Stage IIIb 58 infusional 5-FU/LV 58 follicular Non Hodgkin 58 intra abdominal infections 58 alpha1 antitrypsin deficiency 58 B Cell Lymphoma 58 investigational monoclonal antibody 58 ovarian carcinoma 58 Chronic Myelogenous Leukemia CML 58 suppurative 58 Immunohistochemical staining 58 Subgroup analysis 58 trastuzumab Herceptin ® 58 bevacizumab Avastin ® 58 FOLFOX6 chemotherapy regimen 58 Xcytrin R 58 evaluating picoplatin 58 HepDirect prodrug 58 Inhaled nitric oxide 58 MKC# MKC# PP 58 unresectable 58 extracranial 58 squamous non 58 myeloproliferative disorder 58 Erbitux cetuximab 58 HER2 positive metastatic 58 radiolabeled TM# 58 forodesine 58 familial amyloidotic polyneuropathy FAP 58 BRCA deficient 58 rheumatoid arthritis psoriatic arthritis 58 intrahepatic bile duct 58 castration resistant hormone refractory 58 treatment naïve genotype 58 medically inoperable 58 resistant hormone refractory 57 hematological diseases 57 doublet chemotherapy 57 Li Fraumeni Syndrome 57 ovarian breast 57 neoadjuvant treatment 57 metastatic HRPC 57 refractory chronic lymphocytic 57 bevacizumab Avastin R 57 histone deacetylase HDAC inhibitor 57 thalidomide Thalomid 57 oral clodronate 57 intralesional 57 EGFr humanized monoclonal antibody 57 Brentuximab Vedotin SGN 57 glioblastoma multiforme GBM 57 estramustine 57 Synovial 57 registrational trial 57 gastrointestinal stromal tumor GIST 57 PAOD 57 malignant ovarian 57 Relapsed Refractory 57 Pemetrexed 57 Diffuse Large B 57 multicenter phase 57 cetuximab Erbitux 57 oral JAK#/JAK# inhibitor 57 metastatic castrate resistant 57 cytologically confirmed 57 multicenter Phase III 57 GORE TAG Device 57 non squamous 57 metastatic lymph nodes 57 Refractory Hodgkin Lymphoma 57 de novo kidney transplant 57 AERx R 57 multi kinase inhibitor 57 cetuximab Erbitux ® 57 3 registrational trial 57 noninfectious uveitis 57 colorectal carcinoma 57 TNF Tumor Necrosis Factor 57 gastro intestinal inflammation 57 Nodules 57 investigational immunotherapy 57 benign biliary strictures 57 galiximab 57 metaglidasen 57 acyclovir Lauriad R 57 Temodar ® 57 Septin9 biomarker 57 metastatic breast 57 HCV NS5B polymerase 57 pediatric acute lymphoblastic 57 prostate cancer CRPC 57 Peginterferon alfa 2b 57 Rindopepimut 57 Toxicities 57 oncolytic virus therapies 57 pegylated interferon peg IFN 57 ViaDerm hPTH #-# 57 metastatic castration resistant 57 cisplatin chemotherapy 57 Phase #/#a trial 57 Vandetanib 57 alkylating agent 57 gemcitabine cisplatin 57 INS# [001] 57 MVA MUC1 IL2 57 Metastatic breast cancer 57 Achieves Primary Endpoint 57 relapsed acute lymphoblastic 57 MALT lymphoma 57 transabdominal 57 vaccines oncolytic virus 57 uterus fallopian tubes 57 adjuvant cisplatin 57 novel emulsion formulation 57 fistulizing Crohn disease 57 hepatic tumors 57 Metastatic Melanoma 57 PDX pralatrexate 57 neuropathic pain spasticity 57 ® lenalidomide 57 plasma kallikrein inhibitor 57 intestinal metaplasia 57 sapacitabine CYC# 57 Carfilzomib 57 epirubicin cyclophosphamide 57 ara C 57 R lenalidomide 57 myelofibrosis MF 57 Archexin 57 chronic thromboembolic pulmonary 57 modified glutathione analog 57 RhuDex ® 57 relapsed multiple myeloma 57 pancreatic islet cell 57 Irinotecan 57 oral cavity pharynx 57 peritumoral brain edema 57 INxin 57 EXPAREL TM 57 phase IIb trial 57 metastatic renal cell carcinoma 57 ductal adenocarcinoma 57 Naive Patients 57 IV malignant melanoma 57 mycosis fungoides 57 hip osteonecrosis avascular 57 relapsed leukemia 57 Microplasmin 57 subependymal giant cell 57 thetreatment 57 Kinoid 57 alpha folate receptor 57 ToGA 57 PROSTVAC ® 57 acute promyelocytic leukemia APL 57 EndoTAGTM 1 57 AERx ® 57 Radiation Therapy SIRT 57 lace inset 57 sinonasal 57 colon rectal 57 underwent resection 57 Phase Ib clinical trials 57 advanced unresectable 57 non hodgkin lymphoma 57 HGS# 57 Picoplatin Efficacy After 57 R roscovitine CDK cyclin 57 Patients Treated With 57 rhabdoid 57 MCSP respectively 57 Daclizumab 57 commercialize deforolimus 57 Temsirolimus 57 BRAF gene mutations 57 ACTEMRA TM 57 squamous 57 Allovectin 7 57 TAXOTERE ® 57 liposarcoma 57 farletuzumab 57 phase IIa clinical 57 Fibrin MB 57 PLX STROKE targeting 57 IMPDH inhibitor 57 Glioblastoma Multiforme GBM 57 longus tendon 57 CA4P 57 CTAP# 57 immunohistochemical staining 57 histologically proven 57 DEB# 57 OMP #R# 57 goserelin 57 Selective Internal 57 basal bolus regimen 57 motesanib 57 HER2 positive cancers 57 refractory multiple myeloma 57 Acute Myeloid Leukaemia AML 57 cutaneous T cell 57 Curaxin CBLC# 57 neratinib 57 Zenvia ™ 57 refractory prostate cancer 57 SinuNase ™ 57 epithelial tumors 57 Elestrin ® 56 assessing T DM1 56 PLX MS 56 Azacitidine 56 ANCA associated 56 registrational Phase 56 pediatric pontine glioma 56 pulmonary metastases 56 Percutaneous vertebroplasty 56 Immunotherapeutic 56 neoplasias 56 Fibrin Pad 56 interstitial pneumonitis 56 relapsed ovarian cancer 56 bladder cervix 56 Nexavar sorafenib 56 antimitotic 56 ALN VSP Phase 56 PEG SN# 56 Ophena 56 humanized therapeutic 56 noninvasive outpatient 56 CTAP# Capsules 56 membranous nephritis 56 nonmelanoma skin cancers 56 miconazole Lauriad R 56 ELOXATIN 56 diarrhea predominant irritable 56 pediatric Crohn disease 56 Hexvix ® 56 Allovectin 7 ® 56 medullary thyroid 56 Budesonide foam crofelemer 56 adalimumab Humira 56 skeletal metastases 56 CD# monoclonal antibody 56 bleomycin 56 squamous carcinoma 56 erlotinib Tarceva ® 56 ultrasonographic examination 56 patientswith 56 Sipuleucel T 56 pelvic malignancies 56 BR.# 56 esophagogastric junction 56 Camptosar ® 56 anthracycline taxane 56 vitreous floaters 56 AKT inhibitor 56 IIIA NSCLC 56 carcinomas 56 S Travares Tillman 56 polyneuropathy HIV DSP 56 Epratuzumab 56 intravesical instillation 56 Clolar ® 56 hormone refractory metastatic prostate 56 Ceflatonin 56 hepatoma 56 esophageal cancers 56 TNFerade TM 56 pralatrexate injection folate analogue 56 topically applied SEPA 56 EGFR mutation positive 56 thymic carcinoma 56 denileukin diftitox 56 Golimumab 56 advanced pancreatic neuroendocrine 56 abnormal hematopoietic cells 56 ALN HPN 56 oral prodrug 56 small molecule tyrosine 56 combretastatin A4 phosphate CA4P 56 malignant fibrous histiocytoma 56 Recurrent Chest Wall 56 Occlusive Disease 56 TheraCIM 56 Insegia 56 tumor angiogenesis inhibitors 56 radiation chemoradiation 56 docetaxel Taxotere 56 biliary tract 56 invasive candidiasis 56 Ambrisentan 56 ritonavir boosted 56 dacarbazine DTIC 56 RhuDex TM 56 grade cervical intraepithelial 56 etanercept Enbrel 56 IMiDs ® 56 PI3K/Akt pathway inhibitor 56 basiliximab 56 refractory metastatic colorectal cancer 56 Tesetaxel 56 progressive metastatic prostate 56 TRAIL R1 56 Cutaneous T 56 spinal metastases 56 cytogenetic abnormalities 56 Philadelphia Chromosome Positive 56 carcinoid tumor 56 minimally symptomatic 56 Ixempra 56 Xelox 56 sorafenib Nexavar ® 56 metastatic hormone refractory 56 imatinib Gleevec ® 56 tiuxetan 56 itraconazole Sporanox 56 aflibercept 56 hypereosinophilic syndrome 56 weekly subcutaneous injections 56 metastatic bone 56 hematologic toxicity 56 intravenous RSD# 56 esophagus colon 56 Cloretazine 56 hyperplastic 56 alfa 2a 56 Myelodysplastic Syndrome MDS 56 gastric carcinoma 56 multicentric 56 FOLPI 56 cutaneous squamous cell carcinoma 56 gemcitabine chemotherapy 56 Neoadjuvant 56 TO AVOID PREGNANCY WHILE 56 ß blockers 56 drug GAP #B# 56 Second Pivotal Phase 56 atypical Hemolytic Uremic Syndrome 56 benign neoplasms 56 GW# [003] 56 Zarnestra 56 Fine needle aspiration 56 Epirubicin 56 BLP# Liposome Vaccine 56 paclitaxel Taxol R 56 collagen sponge seeded 56 Ribavirin causes 56 ixabepilone 56 obatoclax 56 rALLy clinical trial 56 Squamous 56 lung ovarian 56 neoplasia CIN 56 NS5B polymerase 56 Luteinizing Hormone Releasing Hormone 56 refractory NSCLC 56 malignant pleural mesothelioma 56 irinotecan chemotherapy 56 intra arterial chemotherapy 56 Paraplatin ® 56 urogenital tract 56 Recurrent Glioblastoma 56 Neulasta R 56 cyclophosphamide chemotherapy 56 investigational humanized monoclonal antibody 56 anthracycline chemotherapy 56 cytokine refractory 56 lymphadenopathy 56 gemcitabine Gemzar 56 AAG geldanamycin analog 56 Intravitreal injections 56 multiple myeloma MM 56 cytotoxic therapy 56 osteoid osteoma 56 acute GvHD 56 Selective Electrochemical Tumor Ablation 56 aurora kinase inhibitor 56 Adenoviral 56 pharmacokinetic PK study 56 trigeminal ganglia 56 Xeloda capecitabine 56 IIIb 56 renal failure interstitial lung 56 Tyrima 56 unresectable liver cancer 56 metastatic CRC 56 peritoneal carcinomatosis 56 femoral popliteal 56 Vitrasert R 56 cholelithiasis 56 vascular disrupting agent 56 AVASTIN 56 immunocompetent adults 56 Phase Ib II 56 methylnaltrexone bromide 56 myeloid metaplasia 56 lenalidomide dexamethasone 56 Panzem 56 pulmonary alveolar 56 advanced epithelial ovarian 56 Aurora Kinase 56 doxorubicin cyclophosphamide 56 Basal Cell 56 urothelial bladder cancer 56 psoriasis inflammatory bowel 56 Dose Ranging Study 56 NV1FGF 56 Tanespimycin 56 midstage clinical trials 56 Endologix Powerlink System 56 CCR9 antagonist 56 melanoma ovarian 56 LymphoStat B TM 56 lymphoid malignancies 56 CHAMPION PCI 56 Dendreon investigational 56 docetaxel chemotherapy 56 recurrent metastatic ovarian cancer 56 Ozarelix 56 Panzem R NCD 56 Azixa 56 pT2 56 sunitinib Sutent ® 56 Afatinib 56 ovarian endometrial 56 OncoVEX GM CSF 56 Meets Primary Endpoint 56 uterine cervix 56 cilengitide 56 Crizotinib 56 DG# compounds targeting 56 hepatocellular carcinoma HCC 56 Akt inhibitor 56 PKC# 56 Zorbtive TM 56 histone deacetylase inhibitor 56 Monoclonal antibody 56 mucinous 56 Histologically 56 Pivotal Trial 56 Rigel R# 56 vinorelbine tartrate 55 Pharmacokinetics PK 55 Xanafide 55 Ewings sarcoma 55 Chronic HCV 55 samalizumab 55 ARG# 55 TNFerade ™ 55 Prospective Randomized 55 somatostatin receptors 55 baminercept 55 precancerous condition 55 cutaneous melanoma 55 RAV# 55 PROSTVAC VF 55 malignant lymphoma 55 squamous cell 55 pharmacogenomic translational research 55 breast carcinoma 55 cervix colon 55 Cytoxan 55 evaluating Prochymal 55 romidepsin 55 oral picoplatin 55 cause mesothelioma asbestosis 55 occlusion CRVO 55 idiopathic thrombocytopenic purpura 55 Simulect 55 Systemic Sclerosis 55 nab paclitaxel 55 Nexavar ® 55 locoregional disease 55 heavily pretreated 55 multicenter randomized controlled 55 Eculizumab 55 tramiprosate Alzhemed TM 55 IL# PE#QQR 55 colon esophageal 55 IMPACT DCM 55 HQK 55 Introgen ADVEXIN 55 gastrointestinal malignancies 55 advanced medullary thyroid 55 SIR Spheres 55 neurologic progression 55 treat chronic sinusitis 55 thick cinching belts 55 Shows Promise Against 55 desmoplastic 55 peripheral arterial occlusive disease 55 IMA# 55 Glufosfamide 55 primitive neuroectodermal tumor 55 biologic DMARD 55 Rituxan rituximab 55 Initiates Phase II 55 pemphigus vulgaris 55 endobronchial 55 premalignant 55 TG# [003] 55 p# biomarker 55 Kit CD# positive 55 hormone refractory prostate cancer 55 Tykerb lapatinib 55 descending thoracic 55 endometrial breast 55 EGFR HER2 55 Gemzar gemcitabine 55 Lubiprostone 55 anaplastic thyroid carcinoma 55 midstage clinical 55 histologic subtype 55 glucocorticoid induced osteoporosis 55 lexidronam injection 55 rFVIIa 55 paragangliomas 55 lung liver pancreas 55 trastuzumab DM1 55 ongoing Phase 1b 55 myelogenous leukemia 55 endoluminal stent graft 55 docetaxel cisplatin 55 HRPC ovarian cancer 55 Zolinza 55 immunohistochemical 55 Histopathologic examination 55 pouchitis 55 Solazed 55 Carotid arteries 55 nodular lesions 55 mRCC 55 metastatic medullary thyroid 55 Carcinoma 55 chronic lymphocytic 55 refractory indolent non 55 VA# [002] 55 neoadjuvant therapy 55 INCB# [003] 55 TRO# 55 Guanilib 55 ARRY # 55 ® chorionic gonadotropin 55 CytoFab ™ 55 tuberous sclerosis TS 55 Alocrest 55 gemcitabine Gemzar ® 55 KSP inhibitor 55 nucleoside analog 55 esophagus pancreas 55 Adjuvant chemotherapy 55 intratumoral injection 55 Hedgehog Pathway Inhibitor 55 diffuse intrinsic pontine glioma 55 ELADUR ™ 55 castration resistant prostate cancer 55 mTOR inhibitors 55 involves inserting catheter 55 Waldenstrom macroglobulinemia 55 Cell Lymphoma 55 Proellex TM 55 cinacalcet 55 debulking surgery 55 stomach duodenum 55 aplastic anemia AA 55 Percutaneous Transluminal Coronary Angioplasty 55 hamartoma 55 intraductal 55 glucokinase activators 55 Lupus Nephritis 55 Methylnaltrexone 55 Zalypsis 55 projectile vomited Vangelo 55 metastatic neuroendocrine tumors 55 cancerous nodules 55 Systemic lupus erythematosus SLE 55 glufosfamide 55 ximelagatran 55 Immunohistochemical analysis 55 HGS ETR1 55 sarcomas